REGN Stock Chart & Stats
$14010.00
$0.00(0.00%)
At close: 4:00 PM EDT
$14010.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$9,470.00 - $15,800.00
Previous CloseN/A
Volume0.00
Average Volume (3M)12.00
Market Cap
$1.57T
Enterprise Value$60.80B
Total Cash (Recent Filing)$7.99B
Total Debt (Recent Filing)$1.99B
Price to Earnings (P/E)19.5
Beta0.31
Next Earnings
Oct 30, 2026EPS Estimate
305.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)41.88
Shares Outstanding101,137,840
10 Day Avg. Volume0
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio3.38
Price to Book (P/B)2.58
Price to Sales (P/S)5.63
P/FCF Ratio19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16,179.96Price Target Upside15.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)1,119.87
Revenue Forecast (FY)$331.18B
Bulls Say, Bears Say
Bulls Say
Dupixent GrowthDupixent combines strong sales growth, a large and expanding patient base, and multi-indication penetration. Its scale and continued label expansion support durable commercial momentum, while the Sanofi partnership provides global reach and shared economics across a broad inflammatory-disease franchise.
Pipeline And Collaboration ExpansionThe expanded Sanofi alliance broadens Regeneron's immunology pipeline while sharing development costs and commercial economics. Lead development and U.S. regulatory roles preserve strategic influence, and milestone potential plus additional partnered options increase long-term pipeline optionality.
Balance Sheet And Cash GenerationVery low leverage and substantial cash generation give Regeneron flexibility to fund research, pursue partnerships, absorb product-cycle volatility, and return capital. The strong capital base reduces financing dependence and supports continued investment in a broad pipeline over multiple years.
Bears Say
Legacy EYLEA DeclineLegacy EYLEA remains exposed to conversion toward EYLEA HD and multiple aflibercept biosimilar launches. Continued erosion in the established franchise can pressure revenue and collaboration economics, requiring rapid HD adoption and other products to offset the structural decline.
Manufacturing DisruptionThe Limerick interruption demonstrates that facility execution can affect reported margins even when underlying product profitability is strong. Although production resumed, disruption-related costs and any recurrence could reduce near-term earnings quality and constrain supply or operating leverage.
Oncology Development ChallengesOncology offers meaningful opportunity but has produced development setbacks and limited near-term commercial scale in some programs. These challenges increase the risk that substantial R&D investment will generate slower or less predictable returns than established immunology products.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $9470.00 and its highest was $15800.00 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $1.57T.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Oct 30, 2026 which is in 2 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Jul 30, 2026. The company reported $266.988 earnings per share for the quarter, beating the consensus estimate of $189.769 by $77.219.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 305.72.
How many shares outstanding does Regeneron have?
Regeneron has 101,137,840 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $266.988 in its last earnings report, beating expectations of $189.769. Following the earnings report the stock price went up 17.128%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in MX:REGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16,179.96 (15.49% Upside)
$16,179.96 (15.49% Upside)
Blogger Sentiment
Bullish
MX:REGN Sentiment 81%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.14%
12-Months-Change
Fundamentals
Return on Equity
13.81%
Trailing 12-Months
Asset Growth
9.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
REGN Company Deck
REGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum driven by Dupixent, rapid EYLEA HD adoption, robust Libtayo growth, an expansive and advancing pipeline with several near-term regulatory catalysts (cemdisiran, PNH data, garetosmab), and a healthy balance sheet with active capital returns. Offsetting risks include a sizable YoY decline for legacy EYLEA U.S., a temporary manufacturing disruption that pressured GAAP margins, timing uncertainty around the EYLEA HD prefilled syringe approval, and acknowledged challenges in oncology development. On balance, positive operating performance, clear growth drivers, and a deep pipeline outweigh the execution and timing risks described.View all MX:REGN earnings summariesREGN Revenue Breakdown
43.99% Net product sales
51.11% Collaboration revenue
4.90% Other revenue
REGN Stock 12 Month Forecast
Average Price Target
$16,179.96
▲(15.49% Upside)